Where bispecific antibodies currently fit into the treatment of multiple myeloma and the distinctions among the currently approved therapies

Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove their worth, so to speak,” said Adams. She discussed the efficacy, route of administration, dosing mechanism of action, and the various tradeoffs among the four bispecific antibodies that the FDA has approved: teclistamab, elranatamab, talquetamab and linvoseltamab.